Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Stryker Corporation (SYK) SEC Filings & Earnings Calls

EquiReason read 18 Stryker Corporation SEC filings in the last 12 months. Latest: 8-K on 2026-10-06 — Stryker announces planned leadership succession: Kevin Lobo transitions to Executive Chair, Spencer Stiles (current President and COO) appointed CEO effective January 1, 2027. Stil.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

SYKStryker CorporationFollow SYK — free
Medical Devices · Healthcare
—
Price chart with a free account
Market cap
117.8B
P/E TTM
31.8
Dividend yield
1.1%
52-week
—
Next earnings
29 Oct, in 5 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

6 Oct 20268-K · 5.02, 7.01Stryker announces planned leadership succession: Kevin Lobo transitions to Executive Chair, Spencer Stiles (current President and COO) appointed CEO effective January 1, 2027. Stiles has nearly 30 years at Stryker; Lobo's 14-year tenure triopen

Risks flagged

Leadership transition risk; potential disruption during handover.

“Leadership transition effective January 1, 2027.” · word for word
Read the original on SEC EDGAR ↗
31 Jul 202610-QStryker reported strong Q2 2026 results with 9.4% sales growth, significant margin expansion, and raised adjusted EPS by 17.9% YoY.earningsopen

Figures in the filing · each found in the filing text

Net Sales · Q2-2026$6.59B+9% y/y
Net Earnings · Q2-2026$1.28B+44% y/y
Adjusted Net Earnings Per Diluted Share · Q2-2026$3.69+18% y/y
Adjusted Operating Income Margin · Q2-202627.4%
Gross Profit Margin · Q2-202668.3%
Operating Cash Flow · H1-2026$1.84B+35% y/y

Risks flagged

Cybersecurity Incident Impact

“higher manufacturing and supply chain costs primarily due to idle production time related to the cybersecurity incident in the first quarter 2026.” · word for word

Segment Mix Pressure on Gross Margin

“we generally expect segment mix to have an unfavorable impact for the foreseeable future as we anticipate more rapid sales growth in our lower gross margin MedSurg and Neurotechnology segment than our Orthopaedics segment.” · word for word
Read the original on SEC EDGAR ↗
30 Jul 20268-K · 2.02Net sales $6.60B (+9% y/y); Organic net sales growth 9; Adjusted operating income margin 27.4; Guidance: Full-year 2026 organic net sales growth guidance narrowed to 8.3%-9.3%, adjusted EPS guidance to $14.95-$15.10earningsopen

Figures in the filing · each found in the filing text

Net sales · Q2-2026$6.60B+9% y/y
Organic net sales growth · Q2-20269.0%
Adjusted operating income margin · Q2-202627.4%
Adjusted EPS · Q2-2026$3.69+18% y/y
Reported EPS · Q2-2026$3.30+44% y/y

Guidance

Full-year 2026 organic net sales growth guidance narrowed to 8.3%-9.3%, adjusted EPS guidance to $14.95-$15.10

Strong Q2 results and raised guidance reflect robust demand and margin expansion

Risks flagged

Cyber incident recovery still in progress

“We made significant progress in our recovery from the cyber incident” · word for word

Pricing pressures and cost-containment measures

“pricing pressures generally, including cost-containment measures that have adversely affected and could in the future adversely affect the price of or demand for our products” · word for word
Read the original on SEC EDGAR ↗
26 Jun 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportSEC ↗
20 May 20268-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportSEC ↗
11 May 202610-QNet Sales $6.02B (+3% y/y); Net Earnings $745M (+14% y/y); Diluted EPS $1.93 (+14% y/y)open

Figures in the filing · each found in the filing text

Net Sales · Q1-2026$6.02B+3% y/y
Net Earnings · Q1-2026$745M+14% y/y
Diluted EPS · Q1-2026$1.93+14% y/y
Adjusted Diluted EPS · Q1-2026$2.60-9% y/y
Gross Profit Margin · Q1-202663.3%
Operating Cash Flow · Q1-2026$581M+132% y/y
MedSurg and Neurotechnology Net Sales · MedSurg and Neurotechnology · Q1-2026$3.21B+5% y/y
Orthopaedics Net Sales · Orthopaedics · Q1-2026$2.81B+0% y/y
Vascular Net Sales · Vascular · Q1-2026$517M+28% y/y
Spinal Implants Net Sales · Spinal Implants · Q1-2026$2M-99% y/y

Risks flagged

Cybersecurity Incident Operational Disruption

“higher manufacturing and supply chain costs primarily due to idle production time related to the cybersecurity incident” · word for word

Tariff Cost Pressure

“In 2025 the United States government announced new tariffs on goods imported into the United States from dozens of countries, including China and the European Union member states.” · word for word

Macroeconomic Slowdown

“The overall macroeconomic and geopolitical environment, including tariffs or changes in trade policies, slower economic growth or recession, market volatility and inflation, and uncertainty regarding all of the foregoing, pose risks that could impact our business and results of operations.” · word for word
Read the original on SEC EDGAR ↗
30 Apr 20268-K · 2.02Net Sales $6.00B (+3% y/y); Organic Net Sales Growth 2.4; Adjusted Operating Income Margin 21.1; Guidance: Organic sales growth 8.0%-9.5%, adjusted EPS $14.90-$15.10earningsopen

Figures in the filing · each found in the filing text

Net Sales · Total · Q1-2026$6.00B+3% y/y
Organic Net Sales Growth · Total · Q1-20262.4%
Adjusted Operating Income Margin · Total · Q1-202621.1%
Adjusted EPS · Total · Q1-2026$2.60-9% y/y
Reported EPS · Total · Q1-2026$1.93+14% y/y
Reported Net Earnings · Total · Q1-2026$745M+14% y/y
MedSurg and Neurotechnology Net Sales · MedSurg and Neurotechnology · Q1-2026$3.20B+5% y/y
Orthopaedics Net Sales · Orthopaedics · Q1-2026$2.80B+0% y/y
Adjusted Net Earnings · Total · Q1-2026$1.00B-9% y/y
Reported Gross Profit Margin · Total · Q1-202663.3%

Guidance

Organic sales growth 8.0%-9.5%, adjusted EPS $14.90-$15.10

Full-year guidance maintained despite weak Q1; management expresses confidence in recovery and momentum.

Risks flagged

Margin compression risk: adjusted operating margin down 180bps, adjusted EPS down 8.5% despite revenue growth.

“Adjusted operating income margin contracted 180 bps to 21.1%.”

Cyber incident disruption: Q1 results impacted by cyber incident; recovery noted but risk of lingering effects.

“I am pleased with our team’s ability to recover quickly from the cyber incident.” · word for word
Read the original on SEC EDGAR ↗
14 Apr 2026SC 13D/ARonda E. Stryker reported a 4% passive beneficial ownership stake in Stryker Corp via Schedule 13D/A, with no plans for control or major changes.SEC ↗
14 Apr 2026SC 13D/ARonda E. Stryker reported a 4% passive beneficial ownership stake in Stryker Corp via Schedule 13D/A, with no plans for control or major changes.SEC ↗
23 Mar 2026DEF 14AStryker filed its definitive proxy statement for the 2026 annual meeting, disclosing executive compensation details, financial performance, and governance practices.open

Figures in the filing · each found in the filing text

Net sales · FY2025$25.12B+11% y/y
Net earnings · FY2025$3.25B+9% y/y
Adjusted net earnings · FY2025$5.27B+12% y/y
Adjusted net earnings per diluted share · FY2025$13.63+12% y/y
Dividends paid per share · FY2025$3.36+5% y/y
Cash, cash equivalents, and marketable securities · FY2025$4.10B+10% y/y
Adjusted operating income · FY2025$6.61B
Free cash flow excluding recall payments · FY2025$4.30B
Adjusted operating income margin · FY202526.5%
Constant currency sales · FY2025$24.99B

Risks flagged

Tariff impact on financial performance

“Even though our financial performance was adversely impacted by tariffs in 2025, the Compensation and Human Capital Committee did not make any adjustments to the calculated 2025 bonus payout for any NEO.” · word for word

Adjusted operating income margin goal not achieved

“However, the adjusted operating income margin goal required for payout of any of the overachievement bonus plan measures was not achieved which resulted in no payout related to the overachievement measures.” · word for word
Read the original on SEC EDGAR ↗
23 Mar 20268-K · 7.01Issued a Regulation FD disclosure (forward guidance or material update); filed financial statements and exhibits with this reportopen

Risks flagged

Cybersecurity incident risk

“Security compromise impacting Entra ID environment, servers, and workstations”
Read the original on SEC EDGAR ↗
12 Mar 20268-K · 7.01Issued a Regulation FD disclosure (forward guidance or material update)open

Risks flagged

Cybersecurity incident causing operational disruption and potential financial impact

“operations continue to be disrupted, including its order processing, manufacturing and shipping” · word for word
Read the original on SEC EDGAR ↗
11 Mar 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open

Risks flagged

Cybersecurity incident may cause operational disruption, data integrity issues, and potential financial impact.

“The incident has caused, and is expected to continue to cause, disruptions and limitations of access to certain of the Company’s information systems and business applications.” · word for word
Read the original on SEC EDGAR ↗
11 Feb 202610-KRisks named: Tariff cost pressure, Incomplete pricing poweropen

Risks flagged

Tariff cost pressure

“Tariffs are expected to continue to result in an increase in certain product costs or have adverse impacts on, among other things, demand for our products and supply chains.” · word for word

Incomplete pricing power

“Although we have been able to pass certain cost increases on to our customers, we have not been able to pass along all cost increases and we cannot guarantee that we will be able to do so in the future, including in connection with proposed or enacted tariffs.” · word for word
Read the original on SEC EDGAR ↗
29 Jan 20268-K · 2.02Reported Net Sales $7.20B (+11% y/y); Organic Net Sales Growth 11; Adjusted EPS $4.47 (+12% y/y); Guidance: FY2026 organic sales growth 8.0%-9.5% (vs FY2025 organic 10.3%); adjusted EPS $14.90-$15.10 (vs FY2025 $13.63, +9.4%-10.8%)earningsopen

Figures in the filing · each found in the filing text

Reported Net Sales · Q4-2025$7.20B+11% y/y
Organic Net Sales Growth · Q4-202511.0%
Adjusted EPS · Q4-2025$4.47+12% y/y
Reported EPS · Q4-2025$2.20+56% y/y
Full Year Reported Net Sales · FY2025$25.10B+11% y/y
Full Year Adjusted EPS · FY2025$13.63+12% y/y
Adjusted Operating Income Margin · Q4-202530.2%
MedSurg and Neurotechnology Organic Sales Growth · MedSurg and Neurotechnology · Q4-202512.6%
Orthopaedics Organic Sales Growth · Orthopaedics · Q4-20258.4%

Guidance

FY2026 organic sales growth 8.0%-9.5% (vs FY2025 organic 10.3%); adjusted EPS $14.90-$15.10 (vs FY2025 $13.63, +9.4%-10.8%)

FY2026 guidance implies continued strong growth with organic sales up 8.0%-9.5% and adjusted EPS up ~10%. CEO cites 'significant momentum' and 'sustained success.'

Risks flagged

Potential impact from foreign exchange, though expected to be slightly positive.

“foreign exchange is expected to have a slightly positive impact on both sales and adjusted net earnings per diluted share” · word for word
Read the original on SEC EDGAR ↗
4 Dec 20258-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)SEC ↗
31 Oct 202510-QStryker reported Q3 2025 revenue growth of 10.3% YoY and adjusted operating margin expansion of 90bps, with strong volume-driven demand across segments.earningsopen

Figures in the filing · each found in the filing text

Net Sales · Q3-2025$6.06B+10% y/y
Net Earnings · Q3-2025$859M+3% y/y
Adjusted Net Earnings Per Diluted Share · Q3-2025$3.19+11% y/y
Operating Cash Flow · 9M-2025$2.90B+26% y/y

Risks flagged

Tariff Impact on Costs and Demand

“Tariffs are expected to result in an increase in certain product costs or have adverse impacts on, among other things, demand for our products and supply chains.” · word for word

Segment Mix Pressure on Gross Margin

“we generally expect segment mix to have an unfavorable impact for the foreseeable future as we anticipate more rapid sales growth in our lower gross margin MedSurg and Neurotechnology segment than our Orthopaedics segment.” · word for word

Integration and Acquisition Costs

“Selling, general and administrative expenses increased $862 or 15.5% in the nine months 2025... primarily due to higher acquisition-related costs and continued investments to support our growth.” · word for word
Read the original on SEC EDGAR ↗
30 Oct 20258-K · 2.02Net Sales $6.10B (+10% y/y); Organic Net Sales Growth 9.5; Adjusted Operating Income Margin 25.6; Guidance: Organic sales growth guidance raised to 9.8-10.2%; adjusted EPS to $13.50-$13.60earningsopen

Figures in the filing · each found in the filing text

Net Sales · Q3-2025$6.10B+10% y/y
Organic Net Sales Growth · Q3-20259.5%
Adjusted Operating Income Margin · Q3-202525.6%
Adjusted EPS · Q3-2025$3.19+11% y/y
Reported EPS · Q3-2025$2.22+3% y/y
MedSurg and Neurotechnology Organic Net Sales Growth · MedSurg and Neurotechnology · Q3-20258.4%
Orthopaedics Organic Net Sales Growth · Orthopaedics · Q3-202511.4%
Full Year Adjusted EPS Guidance · FY2025$13.55

Guidance

Organic sales growth guidance raised to 9.8-10.2%; adjusted EPS to $13.50-$13.60

Strong Q3 beat and guidance raise driven by sustained demand and margin expansion.

Risks flagged

Geopolitical risks including tariffs and trade policy changes.

“geopolitical risks, including from tariffs and the potential for further changes in trade policies and international conflicts” · word for word
Read the original on SEC EDGAR ↗

Stryker Corporation — questions

What did Stryker Corporation file recently?
18 SEC filings in the last 12 months. Latest: 8-K on 2026-10-06 — Stryker announces planned leadership succession: Kevin Lobo transitions to Executive Chair, Spencer Stiles (current President and COO) appointed CEO effective January 1, 2027. Stiles has nearly 30 years at Stryker; Lobo's 14-year tenure tri

Every figure on this page comes from Stryker Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.